Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party
- PMID: 38834689
- DOI: 10.1038/s41409-024-02300-8
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. The median age at transplant was 33.4 years (18.1-75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). More recent years of allo-HSCT were associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS. (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7. J Hematol Oncol. 2021. PMID: 33794963 Free PMC article.
-
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x. J Hematol Oncol. 2019. PMID: 31647022 Free PMC article.
-
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.J Hematol Oncol. 2017 May 30;10(1):113. doi: 10.1186/s13045-017-0480-5. J Hematol Oncol. 2017. PMID: 28558762 Free PMC article.
-
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant. 2019 Jun;54(6):798-809. doi: 10.1038/s41409-018-0373-4. Epub 2018 Nov 1. Bone Marrow Transplant. 2019. PMID: 30385870 Review.
-
The EBMT-ADWP and the CIBMTR.Handb Clin Neurol. 2024;202:295-305. doi: 10.1016/B978-0-323-90242-7.00008-0. Handb Clin Neurol. 2024. PMID: 39111915 Free PMC article. Review.
Cited by
-
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia: Results of a Single-Center Study.Hematol Rep. 2024 Oct 17;16(4):636-647. doi: 10.3390/hematolrep16040062. Hematol Rep. 2024. PMID: 39449305 Free PMC article.
References
-
- Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:580–8. - DOI
-
- Westbrook CA. Molecular subsets and prognostic factors in acute lymphoblastic leukemia. Leukemia 1997;11:S8–10. - PubMed
-
- Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia - PubMed [Internet]. [cited 2023 May 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/28821272/
-
- Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengliné E, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol J Am Soc Clin Oncol. 2013;31:4333–42. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources